Zimbabwe has turned down a major American health deal worth $367m (272 million pounds) over five years due to the United States' request for sensitive biological samples.
The decision came to light following a official document from December was leaked, indicating that Head of State Emmerson Mnangagwa believed the deal was "lopsided".
An official representative later clarified that the US was demanding access to genetic material for research and profit but was unwilling to guarantee the resulting advantages from future treatments.
"We will now turn to the difficult and regrettable process of scaling back our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had provided more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for continued talks to secure a agreement suitable to all parties so the nation's vital HIV programme can proceed.
Wider Implications
This rejection follows a comparable case in neighbouring Kenya, where a court halted a similar deal with the US following concerns were raised about the security of Kenyans' health data.
After resuming the presidency last year, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had administered aid for the American government, but Trump claimed its spending was "wasteful" and his administration was seeking government-to-government agreements to boost openness and accountability.
As per statements, 16 African countries have to date agreed to similar health pacts, representing over $18.3bn of fresh investment.
Details of the Declined Deal
This assistance for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration could have provided extraordinary advantages for Zimbabwean communities, particularly the 1.2 million presently receiving HIV treatment via American-funded programmes," Tremont said.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"Zimbabwe was being asked to share its genetic material and health information for a long time, without any equivalent guarantee of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that could result from that provided information," his statement read.
"Put simply, our country would provide the basic resources for scientific discovery with no assurance that the end products would be accessible to our population should a new pandemic arise."
National Interest and International Frameworks
He also pointed out that the American exit from the global health body and its push of one-on-one health agreements were disrupting frameworks previously set up through the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing scheme created to manage future pandemics.
"This framework is intended to guarantee that when a nation contributes its data, the benefits – including vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We encourage continued discussions with our American counterparts on how future collaboration could be structured in a manner that respects the independence and interests of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it understood the government's concerns, but suggested that talks must proceed considering a large portion of the country's HIV programmes were funded by foreign aid.
"Where specific concerns arise, including those involving data governance or implementation frameworks, these can often be addressed through technical clarification and mutually agreed protections," it said.
This impasse underscores the ongoing challenges between receiving much-needed foreign assistance and protecting a country's data in an increasingly data-driven world.